Have a feature idea you'd love to see implemented? Let us know!

ARWR Arrowhead Pharmaceuticals Inc

Price (delayed)

$23.61

Market cap

$2.94B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5

Enterprise value

$3.35B

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The quick ratio has soared by 72% YoY and by 46% from the previous quarter
The net income has dropped by 192% year-on-year and by 11% since the previous quarter
ARWR's EPS has plunged by 160% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
124.43M
Market cap
$2.94B
Enterprise value
$3.35B
Valuations
Price to book (P/B)
15.83
Price to sales (P/S)
796.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
942.2
Earnings
Revenue
$3.55M
EBIT
-$569.91M
EBITDA
-$551.31M
Free cash flow
-$604.32M
Per share
EPS
-$5
Free cash flow per share
-$5.05
Book value per share
$1.49
Revenue per share
$0.03
TBVPS
$9.44
Balance sheet
Total assets
$1.14B
Total liabilities
$948.74M
Debt
$510.55M
Equity
$185.44M
Working capital
$592.3M
Liquidity
Debt to equity
2.75
Current ratio
6.74
Quick ratio
6.6
Net debt/EBITDA
-0.74
Margins
EBITDA margin
-15,525.6%
Gross margin
100%
Net margin
-16,882.4%
Operating margin
-16,927.1%
Efficiency
Return on assets
-66.5%
Return on equity
-206.7%
Return on invested capital
-60.8%
Return on capital employed
-55%
Return on sales
-16,049.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
5.87%
1 week
-9.3%
1 month
10.64%
1 year
-0.76%
YTD
-22.84%
QTD
21.89%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$601.08M
Net income
-$599.49M
Gross margin
100%
Net margin
-16,882.4%
The operating income has dropped by 193% year-on-year and by 10% since the previous quarter
The net income has dropped by 192% year-on-year and by 11% since the previous quarter
The company's revenue has shrunk by 99% YoY and by 82% QoQ
The gross profit has shrunk by 99% YoY and by 82% QoQ

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.83
P/S
796.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
942.2
ARWR's EPS has plunged by 160% YoY and by 7% from the previous quarter
The equity has contracted by 44% from the previous quarter and by 32% YoY
The price to book (P/B) is 32% higher than the 5-year quarterly average of 12.0 and 26% higher than the last 4 quarters average of 12.6
The company's revenue has shrunk by 99% YoY and by 82% QoQ

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
The company's return on assets has shrunk by 170% YoY
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 125% YoY but it has increased by 13% QoQ
The company's return on equity fell by 20% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 20% higher than its total liabilities
The total liabilities has surged by 98% year-on-year and by 74% since the previous quarter
The quick ratio has soared by 72% YoY and by 46% from the previous quarter
Arrowhead Pharmaceuticals's debt is 175% higher than its equity
The equity has contracted by 44% from the previous quarter and by 32% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.